Targeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infections

dc.contributor.authorMontaner Tarbes, Sergio Roberto
dc.contributor.authorNovell, Elena
dc.contributor.authorTarancón, Vicens
dc.contributor.authorBorrás, Francesc E.
dc.contributor.authorMontoya, Maria
dc.contributor.authorFraile Sauce, Lorenzo José
dc.contributor.authordel Portillo, Hernando A.
dc.date.accessioned2019-01-28T09:42:42Z
dc.date.available2019-01-28T09:42:42Z
dc.date.issued2018
dc.description.abstractThe Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide. Unfortunately, available vaccines are partially effective highlighting the need of novel approaches. Previously, antigenic viral proteins were described in serum-derived extracellular vesicles (EVs) from pigs previously infected with PRRSV. Here, a targeted-pig trial was designed to determine the safety and immunogenicity of such extracellular vesicles enriched fractions. Our results showed that immunizations with EV-enriched fractions from convalescence animals in combination with montanide is safe and free of virus as immunizations with up-to two milligrams of EV-enriched fractions did not induce clinical symptoms, adverse effects and detectable viral replication. In addition, this vaccine formulation was able to elicit specific humoral IgG immune response in vaccinated animals, albeit variably. Noticeably, sera from vaccinated animals was diagnosed negative when tested for PRRSV using a commercial ELISA test; thus, indicating that this new approach differentiates vaccinated from infected animals. Lastly, after priming animals with EV-enriched fractions from sera of convalescence animals and boosting them with synthetic viral peptides identified by mass spectrometry, a distinctive high and specific IFN-γ response was elicited. Altogether, our data strongly suggest the use of serum EV-enriched fractions as a novel vaccine strategy against PRRSV.ca_ES
dc.description.sponsorshipAnti-CD9, Anti-CD63 and anti-CD81 antibodies were kindly donated by Francisco Sánchez-Madrid and Maria Yañez-Mo, Hospital de la Princesa, Madrid, Spain. The authors wish to particularly thank Glòria Abella for her collaboration in conducting the field study and to Marta Alcobé, Miriam Moron Font and Paula Crego Mendez for technical assistance. This study received support from Innovex Therapeutics S.L., Pinsos del Segre SA, Granja Casanyé, Grup de Sanejament Porci (GSP, Lleida, Spain) and the FEDER project (COMRDI16-1-0035-03). Sergio Montanter-Tarbes is an industrial doctorate awarded by the Government of Catalonia, Spain (No. 2014 DI 044). ISGlobal and IGTP are members of the CERCA Programme, Generalitat de Catalunya.ca_ES
dc.identifier.doihttps://doi.org/10.1038/s41598-018-36141-5
dc.identifier.idgrec027585
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/10459.1/65652
dc.language.isoengca_ES
dc.publisherNatureca_ES
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-018-36141-5ca_ES
dc.relation.ispartofScientific Reports, 2018, vol.8, núm.17487, p 1-10ca_ES
dc.rightscc-by (c) Montaner et al., 2018ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectVaccinesca_ES
dc.subjectViral infectionca_ES
dc.titleTargeted-pig trial on safety and immunogenicity of serum-derived extracellular vesicles enriched fractions obtained from Porcine Respiratory and Reproductive virus infectionsca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
027585.pdf
Size:
1.9 MB
Format:
Adobe Portable Document Format
Description:
027583
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: